MwanzoAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
$ 42.02
Baada ya Saa za Kazi:(0.19%)+0.080
$ 42.10
Imefungwa: 29 Apr, 19:15:04 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 41.11
Bei za siku
$ 41.15 - $ 42.36
Bei za mwaka
$ 35.69 - $ 67.66
Thamani ya kampuni katika soko
2.05B USD
Wastani wa hisa zilizouzwa
elfu 350.02
Uwiano wa bei na mapato
16.19
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 178.10M | 31.91% |
Matumizi ya uendeshaji wa biashara | 42.16M | 26.47% |
Mapato halisi | 36.17M | 6.65% |
Kiwango cha faida halisi | 20.31 | -19.15% |
Mapato kwa kila hisa | 0.88 | 20.55% |
EBITDA | 66.80M | 50.95% |
Asilimia ya kodi ya mapato | 11.44% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 256.81M | 46.11% |
Jumla ya mali | 1.51B | 103.90% |
Jumla ya dhima | 873.49M | 309.46% |
Jumla ya hisa | 639.42M | — |
hisa zilizosalia | 48.10M | — |
Uwiano wa bei na thamani | 3.09 | — |
Faida inayotokana na mali | 8.83% | — |
Faida inayotokana mtaji | 10.66% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 36.17M | 6.65% |
Pesa kutokana na shughuli | 23.86M | 56.73% |
Pesa kutokana na uwekezaji | -103.05M | -44,899.56% |
Pesa kutokana na ufadhili | -47.08M | -191.32% |
Mabadiliko halisi ya pesa taslimu | -126.51M | -10,938.92% |
Mtiririko huru wa pesa | 15.61M | 11.18% |
Kuhusu
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Ilianzishwa
1996
Makao Makuu
Tovuti
Wafanyakazi
1,761
